scholarly journals EP-1414 SBRT for the treatment of hepatocellular carcinoma: a retrospective multicenter study

2019 ◽  
Vol 133 ◽  
pp. S768-S769
Author(s):  
N. Scher ◽  
F.G. Riet ◽  
G. Janoray ◽  
K. Debbi ◽  
S. Levy ◽  
...  
Kanzo ◽  
2000 ◽  
Vol 41 (3) ◽  
pp. 169-182
Author(s):  
Toshihito SEKI ◽  
Yukio OSAKI ◽  
Hiroshi KASUGAI ◽  
Hiroko OKA ◽  
Masatoshi KUDO ◽  
...  

Kanzo ◽  
2003 ◽  
Vol 44 (11) ◽  
pp. 546-551 ◽  
Author(s):  
Hiroko OKA ◽  
Yukio OSAKI ◽  
Hiroshi KASUGAI ◽  
Masatoshi KUDO ◽  
Toshihito SEKI ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Dong Ho Lee ◽  
Sangyoun Hwang ◽  
Young Hwan Koh ◽  
Kyung-Hun Lee ◽  
Ju Yeon Kim ◽  
...  

Immune response evaluation criteria in solid tumors (iRECIST) is recommended during immune checkpoint inhibitors (ICIs) treatment, due to the possibility of pseudoprogression. We evaluated the frequency of pseudoprogression in hepatocellular carcinoma (HCC) patients. This retrospective multicenter study involved 158 consecutive patients who underwent nivolumab treatment for HCC in Korea. At the initial evaluation, 94 patients presented with immune unconfirmed progressive disease, and 22 continued nivolumab. At the second evaluation, 21 of the 22 patients (95.5%) had confirmed progression and no pseudoprogression was observed. Considering low possibility of pseudoprogression, iRECIST may not be required for HCC.


Sign in / Sign up

Export Citation Format

Share Document